BioMarin's increasing profitability is also ... They might be being treated in pediatric offices today. and that is precisely why we are really, really focused on ensuring that there is broad ...

Additionally, the company also procured the ‘940 patent from the U.S. Patent and Trademark Office that protects ... In the past 30 days, estimates for BioMarin Pharmaceutical’s 2025 earnings ...

He joined King & Spalding in its Washington, D.C., office in May 2020 and represented ... The RealReal Inc., BioMarin Pharmaceutical Inc., Alliance for Responsible Atmospheric Policy, and National ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

Oppenheimer upgrades BioMarin on long term outlook Amgen India opens with $200 million investment plan through 2025 National Grid sells $1.7 billion US renewables arm to Brookfield ...

BioMarin Pharmaceutical (NASDAQ:BMRN), a leader in developing innovative therapies for rare genetic disorders, reported fourth-quarter 2024 financial results on Wednesday, Feb. 19, that topped ...

BioMarin Pharmaceutical has a twelve month low of $60.63 and a twelve month high of $94.85. The stock has a market cap of $13.56 billion, a price-to-earnings ratio of 32.35, a P/E/G ratio of 0.61 ...

BioMarin Pharmaceutical Stock Up 0.1 % BMRN opened at $70.60 on Friday. The firm has a 50 day moving average price of $66.16 and a 200 day moving average price of $69.10. The company has a market ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...